PT - JOURNAL ARTICLE AU - Emily J. Hill AU - C. Grant Mangleburg AU - Isabel Alfradique-Dunham AU - Brittany Ripperger AU - Amanda Stillwell AU - Hiba Saade AU - Sindhu Rao AU - Oluwafunmiso Fagbongbe AU - Rainer von Coelln AU - Arjun Tarakad AU - Christine Hunter AU - Robert J. Dawe AU - Joseph Jankovic AU - Lisa M. Shulman AU - Aron S. Buchman AU - Joshua M. Shulman TI - Quantitative mobility measures complement the MDS-UPDRS for characterization of Parkinson’s disease heterogeneity AID - 10.1101/2020.08.16.20175596 DP - 2020 Jan 01 TA - medRxiv PG - 2020.08.16.20175596 4099 - http://medrxiv.org/content/early/2020/08/17/2020.08.16.20175596.short 4100 - http://medrxiv.org/content/early/2020/08/17/2020.08.16.20175596.full AB - Introduction Emerging technologies show promise for enhanced characterization of Parkinson’s Disease (PD) motor manifestations. We evaluated quantitative mobility measures from a wearable device compared to the conventional motor assessment, the Movement Disorders Society-Unified PD Rating Scale part III (motor MDS-UPDRS).Methods We evaluated 176 subjects with PD (mean age 65, 65% male, 66% H&Y stage 2) at the time of routine clinic visits using the motor MDS-UPDRS and a structured 10-minute motor protocol, which included a 32-ft walk, Timed Up and Go (TUG), and standing posture with eyes closed, while wearing a body-fixed sensor (DynaPort MT, McRoberts BV). Regression models examined 12 quantitative mobility measures for associations with (i) motor MDS-UPDRS, (ii) motor subtype (tremor dominant vs. postural instability/gait difficulty), (iii) Montreal Cognitive Assessment (MoCA), and (iv) physical functioning disability (PROMIS-29). All analyses included age, gender, and disease duration as covariates. Models iii-iv were secondarily adjusted for motor MDS-UPDRS.Results Quantitative mobility measures from gait, TUG transitions, turning, and posture were significantly associated with motor MDS-UPDRS (7 of 12 measures, p< 0.05) and subtype (6 of 12 measures, p< 0.05). Compared with motor MDS-UPDRS, several quantitative mobility measures accounted for ∼1.5-fold increased variance in either cognition or physical functioning disability. Among minimally-impaired subjects within the bottom quartile of motor MDS-UPDRS, including subjects with normal gait exam, the measures captured substantial residual motor heterogeneity.Conclusion Clinic-based quantitative mobility assessments using a wearable sensor captured features of motor performance beyond those obtained with the motor MDS-UPDRS and may offer enhanced characterization of disease heterogeneity.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFunding Sources: EJH was supported by the Parkinson Study Group / Parkinson Foundation Mentored Clinical Research Award and the National Human Genome Research Institute Medical Genetics Research Fellowship (T32GM007526-41). JMS was supported by Huffington Foundation and a Career Award for Medical Scientists from the Burroughs Welcome Fund. LMS was supported by the NIH and the Rosalyn Newman Foundation. RJD was supported by the National Institute on Aging Mentored Quantitative Research Development Award (K25AG61254). AB received support from NIH (R01AG056352, R01AG017917, RF1AG022018). JJ received research/training funding from AbbVie Inc, CHDI Foundation, Dystonia Coalition, Hoffmann-La Roche Ltd, Michael J Fox Foundation for Parkinson Research, National Institutes of Health, Parkinson Foundation, Parkinson Study Group, Roche, and Teva Pharmaceutical Industries Ltd.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Baylor College of Medicine Institutional Review Board. Subjects with PD were recruited during routine follow-up visits at the Baylor Parkinson Disease Center and Movement Disorders Clinic (PDCMDC).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data referred to in the manuscript is included in the manuscript tables & figures and/or is available on request from the corresponding author.